69 related articles for article (PubMed ID: 19124479)
1. Plasma retinol and prognosis of postmenopausal breast cancer patients.
Formelli F; Meneghini E; Cavadini E; Camerini T; Di Mauro MG; De Palo G; Veronesi U; Berrino F; Micheli A
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):42-8. PubMed ID: 19124479
[TBL] [Abstract][Full Text] [Related]
2. Plasma testosterone and prognosis of postmenopausal breast cancer patients.
Micheli A; Meneghini E; Secreto G; Berrino F; Venturelli E; Cavalleri A; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Veronesi U; Formelli F
J Clin Oncol; 2007 Jul; 25(19):2685-90. PubMed ID: 17548841
[TBL] [Abstract][Full Text] [Related]
3. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
4. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
[TBL] [Abstract][Full Text] [Related]
6. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Formelli F
J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
[TBL] [Abstract][Full Text] [Related]
7. Serum enterolactone and prognosis of postmenopausal breast cancer.
Buck K; Vrieling A; Zaineddin AK; Becker S; Hüsing A; Kaaks R; Linseisen J; Flesch-Janys D; Chang-Claude J
J Clin Oncol; 2011 Oct; 29(28):3730-8. PubMed ID: 21900115
[TBL] [Abstract][Full Text] [Related]
8. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
9. Obesity and outcomes in premenopausal and postmenopausal breast cancer.
Loi S; Milne RL; Friedlander ML; McCredie MR; Giles GG; Hopper JL; Phillips KA
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1686-91. PubMed ID: 16030102
[TBL] [Abstract][Full Text] [Related]
10. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
11. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
12. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum levels of follicle stimulating hormone (FSH) and prognosis in invasive breast cancer.
Eskelinen M; Nordén T; Lindgren A; Wide L; Adami HO; Holmberg L
Eur J Surg Oncol; 2004 Jun; 30(5):495-500. PubMed ID: 15135476
[TBL] [Abstract][Full Text] [Related]
14. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
16. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer.
Kabat GC; Kim M; Caan BJ; Chlebowski RT; Gunter MJ; Ho GY; Rodriguez BL; Shikany JM; Strickler HD; Vitolins MZ; Rohan TE
Int J Cancer; 2009 Dec; 125(11):2704-10. PubMed ID: 19588485
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for male breast cancer: similarity to female counterparts.
Yu E; Stitt L; Vujovic O; Joseph K; Assouline A; Au J; Younus J; Perera F; Tai P
Anticancer Res; 2013 May; 33(5):2227-31. PubMed ID: 23645780
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
19. Serum biomarker 3144 m/z for prognostic detection in Chinese postmenopausal breast cancer patients.
Gao Y; Xu S; Cao W; Chen Z; Wang X; Zou D
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C68-73. PubMed ID: 26323928
[TBL] [Abstract][Full Text] [Related]
20. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
